1. Home
  2. STKE vs MGNX Comparison

STKE vs MGNX Comparison

Compare STKE & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STKE

Sol Strategies Inc. Common Shares

N/A

Current Price

$2.60

Market Cap

95.8M

Sector

N/A

ML Signal

N/A

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$1.37

Market Cap

94.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STKE
MGNX
Founded
2002
2000
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.8M
94.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
STKE
MGNX
Price
$2.60
$1.37
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
$3.20
AVG Volume (30 Days)
221.3K
1.2M
Earning Date
01-29-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,342,517.00
$127,626,000.00
Revenue This Year
$43.15
N/A
Revenue Next Year
$39.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.07
$0.99
52 Week High
$34.32
$3.64

Technical Indicators

Market Signals
Indicator
STKE
MGNX
Relative Strength Index (RSI) N/A 41.08
Support Level N/A $1.33
Resistance Level N/A $1.47
Average True Range (ATR) 0.00 0.10
MACD 0.00 -0.00
Stochastic Oscillator 0.00 14.63

Price Performance

Historical Comparison
STKE
MGNX

About STKE Sol Strategies Inc. Common Shares

Sol Strategies Inc is engaged in investing in blockchain technologies and crypto currencies. Company executes its Investment Objective through three lines of effort: Treasury management: Maintaining a core portfolio of cryptocurrencies for long-term growth, enhanced with risk management strategies to minimize volatility, and generating yield through lending, staking, and liquidity provisioning; Private equity focused on early stage companies in the DeFi and blockchain sectors; and Active investments to generate yield through strategic activities, including Bitcoin mining and stalking and validating Solana.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: